You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)控股子公司與愛科諾簽訂許可協議
格隆匯 08-29 18:20

格隆匯8月29日丨復星醫藥(02196.HK)發佈公吿,2025年8月29日,公司控股子公司復星醫藥產業與愛科諾簽訂《許可協議》,復星醫藥產業獲愛科諾授予(1)AC-201分子、及(2)任何含有AC-201分子為活性成分的藥物於許可區域(即中國境內及港澳地區)及領域(即用於人類疾病的診斷、預防和治療)獨佔的研究、開發、生產、註冊及商業化權利。

AC-201是愛科諾自主研發的口服小分子JAK抑制劑,主要擬用於自身免疫性疾病領域。截至本公吿日期(即2025年8月29日,下同),AC-201的首個適應症(中重度斑塊型銀屑病)已於中國境內完成II期臨牀試驗。根據截至目前的臨牀試驗數據,AC-201展現出良好的安全性及耐受性,未觀察到嚴重的不良事件;其用於中重度斑塊型銀屑病的II期臨牀試驗數據積極,治療12周後,三個劑量組均達到主要終點及關鍵次要終點。根據IQVIA MIDAS最新數據,2024年,JAK抑制劑於全球範圍的銷售額約為168億美元。

愛科諾成立於2017年12月,註冊地為江蘇省蘇州市,法定代表人為Xiaohu Zhang。愛科諾是一家專注於小分子創新藥研發的企業,截至本公吿日期,愛科諾在研管線中的三款藥品已進入臨牀研究階段。截至本公吿日期,愛科諾的註冊資本為4,300萬美元,愛科諾生物醫藥(香港)有限公司持有100%股權;XiaohuZhang為其實際控制人。

根據約定,復星醫藥產業將就本次許可向愛科諾支付至多人民幣15,600萬元(包括首付款及里程碑付款)。

本次合作旨在充分發揮本集團在藥品臨牀開發、註冊、生產和商業化等方面的優勢,進一步豐富本集團自免領域的產品管線、完善市場佈局,從而增強本集團在該治療領域的核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account